Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

@article{Ching2002InductionOE,
  title={Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid},
  author={L. Ching and Z. Cao and C. Kieda and S. Zwain and M. Jameson and B. Baguley},
  journal={British Journal of Cancer},
  year={2002},
  volume={86},
  pages={1937 - 1942}
}
5,6-Dimethylxanthenone-4-acetic acid, synthesised in this laboratory, reduces tumour blood flow, both in mice and in patients on Phase I trial. We used TUNEL (TdT-mediated dUTP nick end labelling) assays to investigate whether apoptosis induction was involved in its antivascular effect. 5,6-Dimethylxanthenone-4-acetic acid induced dose-dependent apoptosis in vitro in HECPP murine endothelial cells in the absence of up-regulation of mRNA for tumour necrosis factor. Selective apoptosis of… Expand
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
TLDR
Results suggest that blood flow inhibition caused by DMXAA is tumour tissue-specific and is a consequence of induction of apoptosis in tumour vascular endothelial cells. Expand
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
TLDR
The results suggest an important role for tumour necrosis factor in mediating both the host toxicity and antitumour activity of 5,6-dimethylxanthenone-4-acetic acid, but also suggest that tumour Necrosis factor can be replaced by other vasoactive factors in its antitumours action, an observation of relevance to current clinical studies. Expand
p38 Mitogen-Activated Protein Kinase Is Required for the Antitumor Activity of the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-acetic Acid
TLDR
In vivo p38 MAPK inhibition attenuated the immediate reduction in tumor blood flow induced by DMXAA treatment by inhibiting actin cytoskeleton reorganization in tumor vascular endothelial cells and blunted the long-lastingDMXAA-induced shutdown of the tumor vasculature by inhibited intratumoral TNF-α production. Expand
Activation of apoptosis by 1-hydroxy-5,7-dimethoxy-2-naphthalene-carboxaldehyde, a novel compound from Aegle marmelos.
TLDR
The data suggest that the novel compound HDNC (marmelin) is a potent anticancer agent that induces apoptosis during G(1) phase of the cell cycle and could be a potential chemotherapeutic candidate. Expand
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
TLDR
The results suggest that p38 MAP kinase plays an important role in the action of DMXAA and that growth of tumour cells on Matrigel provides a promising model for further studies on theaction of this drug. Expand
Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability
TLDR
The hypothesis that DMXAA increases tumor vascular permeability both directly and through the induction of other vasoactive mediators, including TNF, might be useful clinically to potentiate theascular permeability of other anticancer modalities such as cytotoxic drugs, antibodies, drug conjugates and gene therapy. Expand
Antivascular therapy of cancer: DMXAA.
TLDR
DMXAA (5,6-dimethylxanthenone-4-acetic acid) has a striking antivascular and in some cases curative effect in experimental tumours, and the next challenge to face is how the antivascular effect of this drug should be exploited for the treatment of human cancer. Expand
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
TLDR
The antitumour action of DMXAA appears to be independent of the ability of the target tumour cell population to induce NF-kappaB expression, as shown by electrophoretic mobility shift assays (EMSAs). Expand
Abstract 930: p38 MAPK is required for the antitumor activity of the vascular disrupting agent DMXAA
TLDR
It was found that p38 MAPK was critically involved in DMXAA-induced cytoskeleton reorganization in endothelial cells and TNF-α production in macrophages, both of which were essential for DMXaa-induced vascular disruption. Expand
Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
TLDR
The combination of DMXAA and PDT led to a reduction in tumor volume and significant delays in regrowth, giving a PDT-dose modification factor of 2.81, suggesting a promising new combination therapy with considerable therapeutic advantage. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
TLDR
The hypothesis that DMXAA, in addition to antivascular effects mediated by tumor necrosis factor-alpha, may have an antiangiogenic effect mediated largely by the induction of IP-10 is supported. Expand
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
TLDR
Results indicate DMXAA acts in vitro on HPBL to co-stimulate TNF production by a wide variety of agents, and suggests that IkappaB kinase is the target that mediates this action. Expand
Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid
Abstract5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a low-molecular-weight biological response modifier scheduled for clinical evaluation, induced synthesis of tumour necrosis factor-α (TNF-α) inExpand
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
TLDR
It is demonstrated that 5-HT and/or bioreductive drugs can improve the therapeutic activity of DMXAA in mice, and that with SN 23816 both approaches can be used together to provide considerably enhanced anti-tumour activity. Expand
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
TLDR
The results suggest that 5,6-MeXAA would be a more active clinical agent than FAA because TNF-alpha induction appears to be a critical factor in the antitumor effects of this class of compounds. Expand
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
TLDR
Results confirm that DMXAA has the novel ability of inducing tumors to synthesize TNF in situ. Expand
Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.
TLDR
Both 5,6 MeXAA and FAA potentiated the effect of TNF-alpha on normal hypoxic endothelial cells; however, under all other conditions, neither drug in combination with T NF-alpha upregulated clotting activity. Expand
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
TLDR
Investigating DMXAA-induced blood flow changes in the MDAH-MCa-4 mammary carcinoma model finds that tumour blood flow reduction is strongly correlated with tumour growth delay, andoadministration of anti-TNF antibody abolishes serum TNF levels and slightly reduces the antitumour effects of DMX AA. Expand
Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Peritoneal macrophages from C3H/HeN mice bearing subcutaneous M-16/C or Spon-2 mammary carcinomas had enhanced tumouricidal activity over control macrophages from non-tumour bearers in response toExpand
Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
TLDR
Co-administration of thalidomide may represent a novel approach to improving selective intra-tumoural TNF-α production and anti-Tumour efficacy of DMXAA. Expand
...
1
2
3
...